Interstitial Lung DiseasesNCT07117253
Interstitial Lung Diseases in Respiratory ICU
An observational study of Interstitial Lung Diseases, run by Sohag University.
Trial summary
This is Prospective observational study to analyze the clinical features, risk factors, outcome,mortality rates in interstitial lung diseases patients who required admission in Respiratory ICU Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Interstitial Lung Diseases
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- 1 Aug 2025to 29 Aug 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients who had diagnosis of interstitial lung diseases required admission in respiratory ICU
Who may be able to join
- Patients who had diagnosis of interstitial lung diseases required admission in respiratory ICU
Who cannot join
- Patients with respiratory diseases other than ILD
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Factors Affecting Outcome of Patients With Interstitial Lung Diseases in Respiratory Intensive Care Unit
This is Prospective observational study to analyze the clinical features, risk factors, outcome,mortality rates in interstitial lung diseases patients who required admission in Respiratory ICU
- Conditions
- Interstitial Lung Diseases
- Keywords
- interstitial lung diseases, outcome in icu
- Medical subject headings
- Lung Diseases, Interstitial
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with Complications of disease
Measured: 1 month after icu admission
Evaluate Length of respiratory ICU stay
Measured: 1 month after icu admission
Assess mortality of patients with interstitial lung diseases in respiratory icu.
Measured: 1 month after icu admission
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2025
- Study start1 Aug 2025 (estimated)
- Primary completion29 Dec 2025 (estimated)
- Study completion29 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Interstitial Lung DiseasesStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yasmine Mamdouh Salah, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07117253
- Sponsor's protocol ID
- Soh-Med-24-10-8MS
- Status last verified
- Oct 2024
- First submitted
- 29 Jul 2025
- Last updated
- 12 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 12 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Factors Affecting Outcome of Patients With Interstitial Lung Diseases in Respiratory Intensive Care Unit
- ClinicalTrials.gov ID
- NCT07117253
- Acronym / sponsor ID
- Soh-Med-24-10-8MS
- Conditions
- Interstitial Lung Diseases
- Keywords
- interstitial lung diseases, outcome in icu
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Aug 2025 (estimated)
- Primary completion
- 29 Dec 2025 (estimated)
- Study completion
- 29 Aug 2026 (estimated)
- First posted
- 12 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is Prospective observational study to analyze the clinical features, risk factors, outcome,mortality rates in interstitial lung diseases patients who required admission in Respiratory ICU
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients who had diagnosis of interstitial lung diseases required admission in respiratory ICU
Key inclusion criteria (1 listed)
- Patients who had diagnosis of interstitial lung diseases required admission in respiratory ICU
Key exclusion criteria (1 listed)
- Patients with respiratory diseases other than ILD
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of participants with Complications of disease
Time frame: 1 month after icu admission
Evaluate Length of respiratory ICU stay
Time frame: 1 month after icu admission
Assess mortality of patients with interstitial lung diseases in respiratory icu.
Time frame: 1 month after icu admission
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Aug 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Interstitial Lung Diseases
RecruitingPhase 2
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)
RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
RecruitingObservational study
Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses
Erdheim-Chester Disease
Recruiting
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Pulmonary Hypertension, Interstitial Lung Disease (ILD)
Not yet recruiting
TBLC vs NIVATS in Interstitial Lung Disease
Interstitial Lung Diseases (ILD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
An observational study of Interstitial Lung Diseases, run by Sohag University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 12 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact yasmine mamdouh salah, resident (+201092243838, yasmne_mamouh_post@med.sohag.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants with Complications of disease (time frame: 1 month after icu admission). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2025.